PrEP During COVID-19 | HIV.gov

PrEP During COVID-19 | HIV.gov

Federal Response Blog Posts PrEP During COVID-19 The Centers for Disease Control and Prevention (CDC) understands that its partners in HIV prevention are facing unprecedented challenges and demands as we continue to battle the COVID-19 pandemic together. CDC has developed guidance for providing PrEP when facility-based services and in-person patient-clinician contact is limited.  LEARN MORE   NIH-Funded AIDS Clinical Trials Group Conducts COVID-19 Treatment Study A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group. LEARN MORE   Are Your HIV Program Clients Eligible for a Special Enrollment Period? Since many Americans have experienced job losses due to COVID-19 that may have also affected their health coverage, we are sharing this information for HIV case managers, benefits coordinators, and program administrators. LEARN MORE

Events Blog Posts CDC Letter – May is Hepatitis Awareness Month Since hepatitis B and hepatitis C are common coinfections among people living with HIV - and many partners across the country work to address both - we are sharing this Dear Partner message from colleagues at the CDC’s Division of Viral Hepatitis about Hepatitis Awareness Month and Hepatitis Testing Day. LEARN MORE